London, UK – In a significant stride towards understanding the complex interplay between ageing and cancer, an international consortium of researchers has uncovered a critical link between age-related mutations in blood cells and aggressive tumour behaviour. Scientists from the Francis Crick Institute, University College London (UCL), Gustave Roussy, and the Memorial Sloan Kettering Cancer Center (MSK) have collaboratively demonstrated that the expansion of mutant blood cells, a phenomenon inherently tied to the ageing process, can directly infiltrate cancerous tumours. This infiltration, termed "tumour infiltrating clonal haematopoiesis" (TI-CH), is now strongly associated with poorer prognoses and reduced survival rates for patients across a spectrum of cancer types.
The findings, published today in the prestigious New England Journal of Medicine, represent a paradigm shift in how we perceive cancer development and progression, highlighting the crucial influence of systemic age-related changes on local tumour dynamics. This discovery not only deepens our understanding of cancer biology but also paves the way for novel diagnostic tools and preventative therapies in an increasingly ageing global population.
Unravelling the Age-Cancer Connection: A New Frontier in Oncology
The global demographic shift towards an older population brings with it an escalating challenge: the rising incidence of age-related diseases, chief among them cancer and cardiovascular disease. Developing effective preventative and therapeutic strategies hinges on a profound understanding of the "biological interface" where age-related genetic changes meet disease pathologies. For decades, cancer research has primarily focused on mutations within the tumour itself. However, this new research compellingly argues for a broader perspective, integrating systemic changes occurring elsewhere in the body, particularly in the blood system.
The focal point of this groundbreaking investigation is a condition known as Clonal Haematopoiesis of Indeterminate Potential (CHIP). CHIP occurs when blood stem cells, the foundational cells responsible for producing all blood components, accumulate specific genetic mutations over time. This accumulation is largely driven by the natural process of ageing, though external environmental factors can also play a role. While the term "indeterminate potential" suggests an uncertain future, CHIP has previously been identified as a significant risk factor for various age-related disorders, most notably cardiovascular disease. Yet, its direct impact on the evolution and aggression of solid cancers – tumours originating in organs like the lung, pancreas, or head and neck – remained largely unexplored until now.
The Research Journey: From Hypothesis to Revelation
The genesis of this comprehensive study lies in a collaborative effort spanning multiple leading research institutions. Researchers meticulously investigated the link between CHIP and cancer, employing a multi-faceted approach that combined detailed genomic analysis with extensive clinical data. The initial phase involved a cohort of over 400 patients diagnosed with lung cancer, recruited as part of the Cancer Research UK-funded TRACERx and PEACE studies. TRACERx (Tracking Cancer Evolution through therapy) is a pioneering study that meticulously tracks the genetic evolution of lung cancers, offering unprecedented insights into how tumours adapt and resist treatment. The PEACE study (Post-mortem Examination of Advanced Cancer Environments) provides crucial data on metastatic tumours, which are the primary cause of cancer-related mortality. To validate their findings on an unprecedented scale, the team then expanded their analysis to include a massive dataset of 49,000 patients with diverse cancer types from the Memorial Sloan Kettering Cancer Center in the United States.
Initial Insights: CHIP’s Ominous Shadow
The first critical step involved a meticulous examination of blood samples from the lung cancer patient cohort to identify the presence of CHIP mutations. Once identified, these genomic signatures were carefully matched with corresponding clinical data, including patient age, cancer stage at diagnosis, treatment responses, and overall survival times. The initial analysis yielded a stark and concerning observation: patients exhibiting CHIP mutations in their blood samples experienced significantly shorter survival periods compared to those without CHIP. Crucially, this association remained robust and statistically significant even after accounting for other confounding variables such such as the patient’s age at diagnosis or the stage at which their cancer was first identified. This early finding strongly suggested that CHIP was an independent prognostic factor, wielding its influence irrespective of these conventional clinical markers.
The Crucial Distinction: Unmasking Tumour Infiltrating Clonal Haematopoiesis (TI-CH)
While the initial association between CHIP and worse outcomes was compelling, the research team pushed further, seeking to understand the precise mechanism of this impact. They embarked on a more detailed investigation of patients with CHIP, asking a pivotal question: were these specific age-related blood cell mutations merely circulating in the bloodstream, or were they actively infiltrating the lung tumours themselves?
The answer proved to be a critical turning point in the study. Researchers discovered that in a substantial proportion of CHIP-positive patients – specifically, 42% – the identical CHIP mutations were indeed present within the lung tumour tissue. This phenomenon, where mutant blood cells actively migrate into and become part of the tumour microenvironment, was christened "tumour infiltrating clonal haematopoiesis" (TI-CH).
The subsequent analysis revealed an even more profound insight: it was TI-CH, rather than the mere presence of CHIP in the blood, that was overwhelmingly associated with the greater risk of cancer relapse and, tragically, cancer-related death. This distinction underscored that the physical presence and interaction of these mutant blood cells within the tumour were the driving forces behind the adverse outcomes, transforming a systemic age-related condition into a direct participant in cancer progression.
This groundbreaking finding received robust support from the PEACE study samples. By examining post-mortem tissues from sites where cancer had metastasised – the primary cause of cancer mortality – the team frequently identified TI-CH mutations within these aggressive metastatic tumours. This provided compelling evidence that TI-CH plays a role not just in primary tumour progression, but also in the dangerous spread of cancer throughout the body.
Deconstructing the Mechanism: Not All Mutations Are Equal
With the strong link between TI-CH and poor patient outcomes established, the scientists delved deeper into the cellular and molecular mechanisms at play. Their objective was to understand how these infiltrating mutant blood cells exerted their detrimental influence within the tumour microenvironment.
Myeloid Cells: The Double-Edged Sword of Immunity
A detailed analysis of the cellular composition within the lung tumours revealed a striking pattern: patients with TI-CH exhibited a marked expansion of myeloid cells. Myeloid cells are a crucial component of the innate immune system, representing a diverse group of cells including macrophages, neutrophils, and dendritic cells. While some immune cells are highly effective at recognizing and destroying cancer cells, myeloid cells present a more complex and often paradoxical role within the tumour microenvironment. Unlike their anti-tumour counterparts, myeloid cells have been extensively shown to regulate inflammation in ways that can inadvertently support tumour progression, angiogenesis (the formation of new blood vessels that feed the tumour), and metastasis. In essence, these expanded myeloid cells, carrying age-related mutations, appeared to be inadvertently fostering a more hospitable and aggressive environment for cancer growth.
The Prominence of TET2 Mutations
The researchers further refined their investigation by examining specific genes affected by CHIP mutations. They discovered that mutations affecting a particular gene called TET2 were disproportionately represented and had a significant impact. TET2 is a vital regulator of blood cell production, playing a crucial role in epigenetic modification – the process by which gene expression is altered without changing the underlying DNA sequence. Across thousands of individuals, TET2 mutant blood cells demonstrated a significantly higher propensity to infiltrate solid tumours.
To confirm the cellular identity of these TET2-mutated infiltrates, the team conducted single-cell analysis on hundreds of individual cells isolated from the tumours of two patients with TI-CH. This high-resolution technique unequivocally confirmed that the TET2 mutations were predominantly present within the myeloid cell population, rather than in other types of immune cells found within the tumour. This pinpointed TET2-mutated myeloid cells as key orchestrators of the adverse tumour microenvironment.
Experimental Validation: Organoids Reveal Accelerated Growth
To move beyond correlational observations and establish a causal link, the research team collaborated with leading experts in blood cancer and CHIP at Dominique Bonnet’s lab, also located at the Francis Crick Institute. This experimental arm of the study involved growing organoids – three-dimensional mini-tumours that mimic the structure and function of actual lung tumours. By co-culturing these lung tumour organoids with TET2 mutant myeloid cells, the scientists were able to directly observe their impact. The results were compelling: the presence of TET2 mutant myeloid cells profoundly remodelled the tumour microenvironment and, critically, significantly accelerated the growth of the tumour organoids. This experimental evidence provided robust mechanistic validation, demonstrating that TET2-mutated myeloid cells are not merely bystanders but active contributors to aggressive tumour behaviour.
Broadening the Horizon: Validation Across Cancer Types
The final phase of this monumental study involved a crucial validation step, undertaken in collaboration with researchers at the Memorial Sloan Kettering Cancer Center (MSK) in the United States. Leveraging MSK’s vast clinical database, the team analysed data from an astounding 49,000 patients diagnosed with a wide array of different cancer types. This expansive dataset allowed the researchers to ascertain whether their findings, initially derived from lung cancer, held true across a broader spectrum of malignancies.
The results from this large-scale validation were unequivocal: across the diverse cohort, the presence of TI-CH consistently emerged as an independent predictor of shorter patient survival. This confirmed that the detrimental impact of tumour-infiltrating mutant blood cells is not confined to lung cancer but is a general phenomenon with widespread implications in oncology.
Interestingly, the study also revealed variability in the prevalence of CHIP and TI-CH across different cancer types. These mutations were found to be more common in cancers notoriously difficult to treat, such as lung cancer, head and neck cancer, and pancreatic cancer. This observation suggests that TI-CH might be a contributing factor to the inherent aggressiveness and poor prognosis associated with these particular malignancies.
Official Responses: Experts Weigh In
The scientific community has reacted with considerable interest to these landmark findings, recognizing their profound implications for cancer research and patient care.
Dr. Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and a lead author on the study, emphasized the immediate relevance of the discovery. "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients," Dr. Pich stated. "This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer. Understanding its role provides a new avenue for intervention."
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and the Chief Investigator for the TRACERx study, highlighted the groundbreaking nature of the interaction observed. "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations,’ age-related CHIP and cancer, providing unprecedented insight into how ageing might impact cancer risk," Professor Swanton remarked. He further articulated the future potential of this research: "As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers."
Implications and Future Directions: A New Era for Cancer Treatment
This comprehensive study marks a pivotal moment in oncology, opening several exciting and critical avenues for future research and clinical application.
1. Confirming Causality and Elucidating Mechanisms:
The immediate next steps for the research team will be to definitively confirm that CHIP directly contributes to adverse cancer outcomes. While the experimental organoid data provides strong mechanistic evidence, further studies are needed to fully detail the exact molecular and cellular mechanisms by which CHIP, particularly TET2 mutant myeloid cells, functionally implicates itself in the development and progression of aggressive cancers. This includes exploring specific signalling pathways activated by these cells within the tumour microenvironment and their precise interactions with tumour cells.
2. Developing Novel Prognostic Tools:
The identification of TI-CH as an independent predictor of shorter survival has immediate clinical relevance. It suggests the potential for developing new diagnostic assays that screen cancer patients for the presence of CHIP and, more importantly, for TI-CH. Identifying patients with TI-CH could allow clinicians to stratify individuals into higher-risk groups, potentially leading to more aggressive or tailored treatment strategies from the outset. This could revolutionize personalized medicine in oncology.
3. Therapeutic Opportunities:
Understanding the specific role of TET2 mutations and myeloid cell expansion in promoting tumour growth opens up new therapeutic targets. Researchers could explore drugs that specifically inhibit the function of TET2-mutated myeloid cells, modulate their inflammatory effects, or prevent their infiltration into tumours. Such interventions could potentially disarm a key mechanism by which age-related changes contribute to cancer aggression, offering a novel approach to improving patient outcomes, especially in hard-to-treat cancers.
4. The Broader Context of Ageing:
This research underscores the growing importance of addressing ageing itself as a fundamental risk factor for numerous diseases, including cancer. If age-related changes in the blood system can profoundly influence cancer progression, it suggests that strategies aimed at mitigating the effects of biological ageing – often referred to as "geroscience" – could have far-reaching benefits for cancer prevention and treatment.
5. Shifting Paradigms in Cancer Research:
The study encourages a shift in the prevailing cancer research paradigm. While tumour-centric approaches remain vital, this work highlights the need for a more holistic view that integrates systemic factors and host-intrinsic characteristics, such as the ageing immune system and blood cell dynamics. Future research will likely explore other systemic age-related changes and their potential impact on various disease processes.
This work was generously supported by Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, alongside additional funders, underscoring the collaborative effort and significant investment required for such impactful scientific discoveries. As the global population continues to age, this groundbreaking research offers a beacon of hope, illuminating new pathways to combat cancer and improve the lives of millions worldwide.
About the Author
